相似文献
1
Design, synthesis, and structure-activity relationship of substrate competitive, selective, and in vivo active triazole and thiadiazole inhibitors of the c-Jun N-terminal kinase.
J Med Chem. 2009 Apr 9;52(7):1943-52. doi: 10.1021/jm801503n.
2
Synthesis and optimization of thiadiazole derivatives as a novel class of substrate competitive c-Jun N-terminal kinase inhibitors.
Bioorg Med Chem. 2010 Jan 15;18(2):590-6. doi: 10.1016/j.bmc.2009.12.013. Epub 2009 Dec 11.
3
Development of thiadiazole as an antidiabetic agent- a review.
Mini Rev Med Chem. 2014 Feb;14(2):136-53. doi: 10.2174/1389557513666140103102447.
4
Design and characterization of a potent and selective dual ATP- and substrate-competitive subnanomolar bidentate c-Jun N-terminal kinase (JNK) inhibitor.
J Med Chem. 2011 Sep 22;54(18):6206-14. doi: 10.1021/jm200479c. Epub 2011 Aug 23.
5
Novel indole based fused triazole-thiadiazole derivatives as anti-diabetic agents: and approaches.
Future Med Chem. 2024;16(23):2475-2486. doi: 10.1080/17568919.2024.2419355. Epub 2024 Nov 7.
6
Discovery of [1,2,4]triazolo[3,4-b][1,3,4]thiadiazole derivatives as novel, potent and selective c-Met kinase inhibitors: Synthesis, SAR study, and biological activity.
Eur J Med Chem. 2018 Apr 25;150:809-816. doi: 10.1016/j.ejmech.2018.03.049. Epub 2018 Mar 21.
7
Development of amino-pyrimidine inhibitors of c-Jun N-terminal kinase (JNK): kinase profiling guided optimization of a 1,2,3-benzotriazole lead.
Bioorg Med Chem Lett. 2013 Mar 1;23(5):1486-92. doi: 10.1016/j.bmcl.2012.12.047. Epub 2012 Dec 22.
8
Synthesis and cytotoxicity evaluation of some novel thiazoles, thiadiazoles, and pyrido[2,3-d][1,2,4]triazolo[4,3-a]pyrimidin-5(1H)-ones incorporating triazole moiety.
Molecules. 2015 Jan 14;20(1):1357-76. doi: 10.3390/molecules20011357.
9
A novel retro-inverso peptide is a preferential JNK substrate-competitive inhibitor.
Int J Biochem Cell Biol. 2013 Aug;45(8):1939-50. doi: 10.1016/j.biocel.2013.06.006. Epub 2013 Jun 19.
10
Synthesis and antimicrobial activity of new 1,2,4-triazole and 1,3,4-thiadiazole derivatives.
J Enzyme Inhib Med Chem. 2008 Apr;23(2):277-84. doi: 10.1080/14756360701408697.
引用本文的文献
1
Halicin: A New Approach to Antibacterial Therapy, a Promising Avenue for the Post-Antibiotic Era.
Antibiotics (Basel). 2025 Jul 11;14(7):698. doi: 10.3390/antibiotics14070698.
2
Halicin Reduces the Warburg Effect and Overcomes Drug Resistance by Activating the Pyruvate Kinase M2 Pathway for Triple-Negative Breast Cancer Treatment.
ACS Omega. 2025 Jun 6;10(23):24541-24554. doi: 10.1021/acsomega.5c01251. eCollection 2025 Jun 17.
3
The Role of the Dysregulated JNK Signaling Pathway in the Pathogenesis of Human Diseases and Its Potential Therapeutic Strategies: A Comprehensive Review.
Biomolecules. 2024 Feb 19;14(2):243. doi: 10.3390/biom14020243.
4
On drug discovery against infectious diseases and academic medicinal chemistry contributions.
Beilstein J Org Chem. 2022 Sep 29;18:1355-1378. doi: 10.3762/bjoc.18.141. eCollection 2022.
5
Repurposing Halicin as a potent covalent inhibitor for the SARS-CoV-2 main protease.
Curr Res Chem Biol. 2022;2:100025. doi: 10.1016/j.crchbi.2022.100025. Epub 2022 Apr 22.
6
Recent Progress in the Synthesis of Drugs and Bioactive Molecules Incorporating Nitro(het)arene Core.
Pharmaceuticals (Basel). 2022 Jun 3;15(6):705. doi: 10.3390/ph15060705.
7
An interpretable machine learning approach to identify mechanism of action of antibiotics.
Sci Rep. 2022 Jun 20;12(1):10342. doi: 10.1038/s41598-022-14229-3.
8
Synergism between the Synthetic Antibacterial and Antibiofilm Peptide (SAAP)-148 and Halicin.
Antibiotics (Basel). 2022 May 17;11(5):673. doi: 10.3390/antibiotics11050673.
9
Evaluation of Anticancer and Antibacterial Activity of Four 4-Thiazolidinone-Based Derivatives.
Molecules. 2022 Jan 28;27(3):894. doi: 10.3390/molecules27030894.
10
Sex and dose-dependent antinociceptive effects of the JNK (c-Jun N-terminal kinase) inhibitor SU 3327 are mediated by CB receptors in female, and CB/CB receptors in male mice in an inflammatory pain model.
Brain Res Bull. 2021 Dec;177:39-52. doi: 10.1016/j.brainresbull.2021.09.004. Epub 2021 Sep 14.
本文引用的文献
1
Identification of a new JNK inhibitor targeting the JNK-JIP interaction site.
Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16809-13. doi: 10.1073/pnas.0805677105. Epub 2008 Oct 15.
2
Development of paramagnetic probes for molecular recognition studies in protein kinases.
J Med Chem. 2008 Jun 26;51(12):3460-5. doi: 10.1021/jm800068w.
3
Discovery of potent, highly selective, and orally bioavailable pyridine carboxamide c-Jun NH2-terminal kinase inhibitors.
J Med Chem. 2006 Jul 27;49(15):4455-8. doi: 10.1021/jm060465l.
4
Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity.
J Med Chem. 2006 Jun 15;49(12):3563-80. doi: 10.1021/jm060199b.
5
Design and synthesis of 2'-anilino-4,4'-bipyridines as selective inhibitors of c-Jun N-terminal kinase-3.
Bioorg Med Chem Lett. 2006 Mar 1;16(5):1397-401. doi: 10.1016/j.bmcl.2005.11.039. Epub 2005 Dec 5.
6
The neuroprotective action of JNK3 inhibitors based on the 6,7-dihydro-5H-pyrrolo[1,2-a]imidazole scaffold.
Bioorg Med Chem Lett. 2005 Nov 1;15(21):4666-70. doi: 10.1016/j.bmcl.2005.07.076.
7
Design and synthesis of 6-anilinoindazoles as selective inhibitors of c-Jun N-terminal kinase-3.
Bioorg Med Chem Lett. 2005 Nov 15;15(22):5095-9. doi: 10.1016/j.bmcl.2005.06.083.
8
Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase.
J Med Chem. 2005 Jul 14;48(14):4596-607. doi: 10.1021/jm0310986.
9
Therapeutic promise of JNK ATP-noncompetitive inhibitors.
Trends Mol Med. 2005 May;11(5):232-9. doi: 10.1016/j.molmed.2005.03.005.
10
Design, synthesis, and biological activity of novel, potent, and selective (benzoylaminomethyl)thiophene sulfonamide inhibitors of c-Jun-N-terminal kinase.
J Med Chem. 2004 Dec 30;47(27):6921-34. doi: 10.1021/jm031112e.
Zotero 插件